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The lack of in vitro prostate cancer models that
recapitulate the diversity of human prostate cancer
has hampered progress in understanding disease
pathogenesis and therapy response. Using a
3D organoid system, we report success in long-
term culture of prostate cancer from biopsy spec-
imens and circulating tumor cells. The first seven
fully characterized organoid lines recapitulate
the molecular diversity of prostate cancer sub-
types, including TMPRSS2-ERG fusion, SPOP mu-
tation, SPINK1 overexpression, and CHD1 loss.
Whole-exome sequencing shows a low mutational
burden, consistent with genomics studies, but
with mutations in FOXA1 and PIK3R1, as well as
in DNA repair and chromatin modifier pathways
that have been reported in advanced disease.
Loss of p53 and RB tumor suppressor pathway
function are the most common feature shared
across the organoid lines. The methodology des-
cribed here should enable the generation of a
large repertoire of patient-derived prostate cancer
lines amenable to genetic and pharmacologic
studies.176 Cell 159, 176–187, September 25, 2014 ª2014 Elsevier Inc.INTRODUCTION
The discovery of molecular biomarkers of drug sensitivity is
paramount for the precision treatment of cancer patients. As
exemplified by gefitinib in non-small-cell lung cancer, many
drugs can lead to extraordinary responses in small subsets of
patients, which, when left unidentified, result in negative clinical
trials (Thatcher et al., 2005). In vitro cell lines, with the capacity
for unlimited growth, amenability to high-throughput screening,
and in vivo testing as xenografts, have been an important
resource in the identification of predictors of response and resis-
tance mechanisms (Druker et al., 1996; Solit et al., 2006). Large-
scale screens of cancer cell line panels that integrate genomic
profiles with sensitivity to a large number of compounds can
identify drugs active in specific genetic contexts that might
otherwise be missed (Barretina et al., 2012; Garnett et al.,
2012). Early results from these studies suggest that genetic alter-
ations and cell lineage are important determinants of drug sensi-
tivity. Therefore, a large number of cell lines are required to study
each specific lineage.
Prostate cancer is the most common malignancy and the
second most common cause of cancer death in Western men.
Despite its prevalence, prostate cancer has proven very difficult
to propagate in vitro and is highly underrepresented with only
seven cell lines among 1,000 cancer cell lines in public repos-
itories (Horoszewicz et al., 1983; Kaighn et al., 1978; Korenchuk
et al., 2001; Mertz et al., 2007; Navone et al., 1997; Sramkoski
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4et al., 1999). Recent advances in genomics technology have
generated a catalog of genetic lesions that underlie prostate
tumorigenesis (Baca et al., 2013; Barbieri et al., 2012; Taylor
et al., 2010), many of which (e.g., SPOPmutation, FOXA1muta-
tion, CHD1 loss) are not represented in available cell lines.
Furthermore, in castration-resistant prostate cancer (CRPC),
where the immense selection pressure of therapy can lead to
significantly increased heterogeneity (Grasso et al., 2012), a
large repository of CRPC lines would be required to represent
different mechanisms of resistance.
We sought to generate in vitro models of prostate cancer
derived from contemporary patients that represent the spectrum
of those undergoing treatment for the disease. We have defined
growth conditions for small intestine, large intestine, pancreas,
and liver, where single epithelial stem cells form organoids that
recapitulate the tissue histology and lineage hierarchy in vitro
(Barker et al., 2010; Huch et al., 2013a; Huch et al., 2013b; Sato
et al., 2009). In the accompany manuscript (Karthaus et al.,
2014, this issue), we developed conditions optimized for contin-
uous propagation of both normal human basal and luminal pros-
tate epithelial cells. Using these prostate specific conditions, we
report success in the generation and detailed molecular charac-
terization of seven human-derivedprostate cancer organoid lines
derived from diverse disease sites including circulating tumor
cells. These lines harbor copynumber signaturesof primarypros-
tate cancer, including SPOP mutation, PTEN loss, TMPRSS2-
ERG interstitial deletion, as well as alterations commonly found
in CRPC including TP53, PIK3R1, FOXA1, and several chromatin
modifier mutations. Further, the organoid lines recapitulate the
phenotypic diversity of CRPC, including AR-dependent adeno-
carcinoma, AR-negative adenocarcinoma, neuroendocrine car-
cinoma, and squamous differentiation. Importantly, these lines
are amenable to drug testing in vitro and in vivo.
RESULTS
Weplated prostate cancermetastasis samples, freshly collected
by tissue biopsy and confirmed by pathology review to have
>10% tumor cell content, into prostate organoid culture and es-
tablished organoid lines from six patients that have been contin-
uously propagated for >6 months. A seventh organoid line was
established from circulating tumor cells (CTCs) of a CRPC pa-
tient with a high CTC count (>100 cells per 8 ml of blood). The
clinical characteristics and prognostic variables (Smaletz et al.,
2002) of the seven patients span the spectrum of advanced pros-
tate cancer (Table 1).
In our hands, the efficiency for establishing continuously prop-
agated organoid lines frommetastatic biopsies was15%–20%
(6 lines from 32 ‘‘attempts’’ of cancer-bearing samples) and
could presumably be improved by further optimization of growth
conditions. It is worth noting that tumor organoids were repro-
ducibly maintained for 1–2 months for70% of soft tissue tumor
biopsies and 30% of bone biopsy biopsies, but many of these
tumor cultureswere overtaken by tumor-associated spindle cells
or normal epithelial cells present in the biopsy material. For
example, two continuously proliferating organoid lines derived
from liver and lung metastases had no copy number alterations
and no mutations of 50 common cancer-associated genes (notCell 159, 176–187, September 25, 2014 ª2014 Elsevier Inc. 177
AB
Figure 1. Copy Number Landscape of Patient Derived Prostate Cancer Organoid Lines
(A) Top: Significant genomic aberrations in the prostate oncogenome from the MSKCC CGH data set adopted from (Taylor et al., 2010). Bottom: Copy number
landscape of seven patient-derived organoid lines and six publically available prostate cancer cell lines using array CGH data. Shades of red and blue represent
level of gain and loss.
(B) Copy number changes at chromosome 3p14 containing FOXP1, SHQ1, and RYBP, the CHD1 locus, the PTEN locus, the TMPRSS2-ERG locus and the AR
locus. Arrows point to highly focal regions of biallelic deletion. See also Figure S1 for zoomed view together with corroborating RNA-seq and WES reads.shown), whichwe interpret asmore consistent with the lines orig-
inating from normal liver or lung epithelial cells rather than from
prostate cancer. Indeed, others have reported that the growth
conditions used here are broadly conducive to growth ofmultiple
normal epithelial cell types (Barker et al., 2010; Huch et al.,
2013a; Huch et al., 2013b; Sato et al., 2009). Strategies to selec-
tively isolate tumor from the normal epithelial and stromal cells
present in biopsies might overcome this problem. In addition,
evaluation of other conditions to improve primary epithelial
growth such as coculture with stromal cells and ROCK inhibitor
(Liu et al., 2012b) might further enhance efficiency. Nonetheless,
the derivation of seven new lines over9months effectively dou-
bles the number of existing prostate cancer cell lines.
Patient-Derived Organoid Lines Have Copy Number
Alteration Signatures of Aggressive Prostate Cancer
Stereotypic recurrent copy number changes found in high-
grade primary and metastatic prostate cancer include gains of178 Cell 159, 176–187, September 25, 2014 ª2014 Elsevier Inc.chromosome 7 and 8q and losses of chromosome 5q, 6q, 8p,
13q, and 18q (Demichelis et al., 2009; Grasso et al., 2012; Tay-
lor et al., 2010). The seven prostate cancer organoid lines
described here exhibit many of these typical copy number
alterations, even more so than currently available prostate
cancer cell lines (Figure 1A). For example, MSK-PCa1 and
MSK-PCa3 exhibit the TMPRSS2-ERG interstitial deletion,
and MSK-PCa1 and MSK-PCa7 harbor focal heterozygous
deletion of SHQ1 and RYBP, both of which map to a region
chromosome 3p14 previously shown to span the candidate tu-
mor suppressors FOXP1, SHQ1, and RYBP (Krohn et al., 2013;
Taylor et al., 2010).
Threeorganoid lines (MSK-PCa2,MSK-PCa4, andMSK-PCa7)
contain focal homozygous deletions of chromodomain helicase
DNA binding protein 1(CHD1), that results in complete loss of
protein expression (Figure 1B, also see Figure 4B). CHD1 is the
second most commonly homozygous deleted gene in prostate
cancer (Burkhardt et al., 2013; Liu et al., 2012a). In MSK-PCa2,
asharpdeletion results in abrupt terminationof the transcript (Fig-
ure 1B, arrow) (Figure S1A available online).
Six of the seven organoid lines harbor focal homozygous dele-
tion of PTEN or the PTEN promoter (Figure 1B, Figure S1B). In
addition, MSK-PCa2 harbors an amplification of AR found in
50% of CRPC. Collectively, the human-derived organoid lines
harbor highly representative copy number alterations of prostate
cancer and CRPC both in terms of overall landscape as well as
highly prostate specific focal deletions.
Patient-Derived Organoid Lines Have a Mutational
Landscape Similar to Prostate Cancer
To catalog mutations present in the patient-derived organoid
lines, we performed whole-exome sequencing (WES) of the or-
ganoid lines and identified somatic alterations by comparison
to matched patient normal DNA (Table S1).
The number of somatic nonsynonymous single-nucleotide
variations (SNV) and indels ranged from 29 in MSK-PCa1 to 75
inMSK-PCa4with amean of 45.4 per sample, consistent with re-
ported mutation frequency in CRPC tissue (Baca et al., 2013;
Barbieri et al., 2012; Grasso et al., 2012) (Figure 2A, Table S2),
and the specific genes are similar to those reported in metastatic
CRPC (Figure 2B, Table S3).
TP53, the most commonly mutated gene in CRPC (Grasso
et al., 2012; Kumar et al., 2011), was mutant in four organoid
samples (Figure 2C). In all cases, only the mutant allele was de-
tected by RNA-seq, with complete loss of p53 function through
either single-copy loss or copy-neutral loss of heterozygosity
(Figure S2A). Mutations in FOXA1, a pioneer transcription factor,
and PIK3R1, the regulatory subunit of PI3-kinase, were also
found in organoid lines and are among the most mutated genes
in CRPC.
The E3 ubiquitin ligase SPOP is the most commonly mutated
gene in primary prostate cancer (10%) (Barbieri et al., 2012).
MSK-PCa7 harbors a heterozygous SPOPF133L mutation within
the substrate recognition domain (a known hotspot in human
samples), making it the only known in vitromodel of this mutation
reported to date (Figure S2B).
We also observed mutations in genes that regulate genomic
stability (ATRX, CHEK2) and in chromatin modifying enzymes
(MED1, KDM4C, KDM4D, MLL2, SETDB1B,and SETD2), all of
which have been reported previously in CRPC (Grasso et al.,
2012). In addition, the organoid lines harbor mutations in two
well-characterized tumors suppressors, TSC2 andCDK12 (Can-
cer Genome Atlas Research Network, 2011).
It is often difficult to discern driver and passenger mutations in
a small sample size. We reasoned that mutations in genes that
are expressed would be more likely to be functional and there-
fore annotated the mutated genes by RNA-seq-based mRNA
levels quantified as reads per kilobase per million mapped reads
(RPKM) (Figure 2C). While most mutated genes are expressed at
very low levels, mutations with high functional likelihood,
including TP53, FOXA1, PIK3R1, and SPOP are all expressed
at high levels. Four additional genes mutated in two samples,
ABHD15, FAM193B, UTRN, and GIT2 demonstrated moderated
to high expression levels and represent potential for follow up.
Among the seven organoid lines, there was enough fresh
frozen tumor tissue to perform WES in two (MSK-PCa2 andMSK-PCa7) specimens.We compared themutational landscape
between the tumor and the patient-derived organoid. We found
four discrepant calls for MSK-PCa2 and seven discrepant calls
for MSK-PCa7, which, upon manual inspection, mapped to
regions of low coverage or repeats and did not represent true
differences (Table S2). Further, there was a high concordance
between the allele frequencies found in the organoid lines and
the corresponding tumor tissue (Figure 2D). In addition, using
RNA-seq data of matched organoid and tumor sample of
MSK-PCa6 (see below for RNA-seq analysis), we examined the
mRNA allele frequency of themutant allele.We found that among
expressed genes with somatic mutations, the allele frequency
was highly concordant between the tumor and organoid line (Fig-
ure 2E). These data indicate that in three organoid samples, the
organoid culture retained the mutational landscape of the tumor.
Two additional patients (MSK-PCa1 and MSK-PCa5) had meta-
static pelvic lymph nodes resected during radical retropubic
prostatectomy 1 year prior to organoid acquisition. We per-
formed WES on the archive formalin-fixed paraffin embedded
(FFPE) lymph node metastasis. Due to possible FFPE artifacts,
we limited analysis to point mutations identified in the organoid
sample. In MSK-Pca1 and MSK-PCa5, respectively, 15/23
(65%) and 23/33 (67%) of point mutations found in the organoid
line were identified in the lymph node metastasis. While we
cannot rule out the possibility that additional mutations were
acquired during the culturing process, this data suggest that
additional mutations were acquired during progression from
hormone-sensitive to castration-resistant metastatic disease.
In addition, several mutations had higher than expected allele
frequencies (above the regression line) in the organoid sample
suggesting further enrichment of the mutant allele (Figure 2E).
Human Prostate Cancer Organoid Lines Recapitulate In
Situ Histology In Vitro and In Vivo
Using organoid growth conditions, normal human epithelial cells
form prostate-like structures in vitro that can be grafted in vivo to
regenerate prostate glands (Karthaus et al., 2014, this issue).
Similarly, the seven organoid lines, and tumor grafts derived
from these organoid lines, also display histological patterns pre-
sent in the original patient sample. For example, the primary can-
cer from which MSK-PCa1 was derived, showed an intraductal
growth pattern (Figure 3A), whereas the bone biopsy specimen
showed only sparse tumor cells that stained positive for pan-cy-
tokeratin (PanCK) and negative for AR (Figure S3A, data not
shown). Remarkably, the organoid lines derived from this bone
marrow metastasis recapitulated the intraductal pattern of the
primary cancer (Figure 3B). IHC showed that the organoids
were positive for pan-cytokeratin and negative for AR, as seen
in the corresponding biopsy specimen (Figure S3A). When
grafted into SCID mice, the tumors recapitulated both the histo-
logical and immunohistological pattern of the patient sample
(Figures 3C and S3A).
The tissue specimens of MSK-PCa2, MSK-PCa3, MSK-PCa6
andMSK-PCa7 showed high-grade adenocarcinoma, mucinous
adenocarcinoma (Johnson et al., 2013), adenocarcinoma with
extensive squamous differentiation (Parwani et al., 2004) and
Gleason pattern 4 adenocarcinoma with cribiform growth, res-
pectively (Figures 3D, 3G, 3P, 3S). The histological pattern ofCell 159, 176–187, September 25, 2014 ª2014 Elsevier Inc. 179
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Figure 2. Mutational Landscape of Patient-Derived Prostate Cancer Organoid Lines
(A) Quantification of number of nonsynonymous single-nucleotide variations (SNV, pink) and insertion-deletions (indel, orange) in each organoid sample
compared to average total SNV and indels of publishedwhole-exome data sets (green). The light blue line represents the averagemutations of the seven organoid
lines.
(B) The alteration rate (green: mutation, including both nonsynonymous SNV, blue: homozygous deletion, red: amplification, gray: multiple alterations) of genes
mutated in the seven organoid samples in prostate cancer data sets.
(legend continued on next page)
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eachof theseoriginal tumors is also retained in theorganoids (Fig-
ures3E,3H, 3Q,3T). TumorsgeneratedbyengraftingMSK-PCa2,
MSK-PCa3, and MSK-PCa6 into SCID mice were reminiscent of
the tumor tissue (Figures 3F, 3I, 3R). Interestingly, the CTC-
derived line MSK-PCa5 also generated organoids and grafts
resembling the primary cancer (Figures 3M, 3N, 3O, and S3E).
MSK-PCa4 is a prostate cancer with treatment-induced
neuroendocrine differentiation isolated from a pleural effusion.
It displays typical small cell features including high nuclear to
cytoplasic ratio, multiple mitotic figures indicative of rapid
proliferation, negative AR and positive synaptophysin staining
both in 3D culture and when grafted in vivo (Figures 3J, 3K, 3L,
and S3D).
In summary, patient-derived organoids retain the micro-
scopic features of the original patient sample across a range
of histologies. However, a single histology tends to emerge
from samples with intratumoral heterogeneity (i.e., MSK-PCa4
with both pan-cytokeratin positive and negative clones and
MSK-PCa6 with both adenocarcinoma and squamous cells
differentiation).
Patient-Derived Organoid Lines Exhibit Diverse
Differentiation Found in CRPC
We performed RNA-seq to catalog the gene expression profile
of the seven organoid lines. As expected, hierarchical clustering
of the profiles shows that the four AR-positive lines form
one cluster, the two AR-negative lines form a second, while
the AR-low line with squamous differentiation forms a third
(Figure S4A).
More focused analysis of mRNA and protein expression of
genes implicated in prostate cancer tumorigenesis and differen-
tiation revealed that the seven organoids also recapitulate the
diversity seen in human tumors (Figures 4A and 4B). MSK-
PCa1 and MSK-PCa3 both harbor the TMPRSS2-ERG intersti-
tial deletion but the AR-negativeMSK-PCa1 no longer expresses
the transcript, consistent with the observation that 50% of
AR-negative CRPC prostate cancer harbor nonexpressed
TMPRSS2-ERG fusion (Schelling et al., 2013). MSK-PCa5 and
MSK-PCa7 are positive for SPINK1, a gene-expression-based
subtype of prostate cancer that is mutually exclusive with ETS
translocations (Tomlins et al., 2008).
Two samples, MSK-PCa2 and MSK-PCa7, are characterized
by high-level AR expression and expression of most AR target
genes, with the exception that MSK-PCa2 has silenced KLK2/
3 expression. MSK-PCa3, MSK-PCa5, and MSK-PCa6 have
lower levels of AR expression but retain expression of selected
AR target genes including STEAP1 and TMPRSS2. MSK-PCa1(C) Table of genes that aremutated inmore than one sample aswell as geneswith
seq-based mRNA expression quantified as reads per kilobase per million mapped
also Table S1 for quality metrics of WES and Table S2 for all a list of all somatic
(D) Scatterplot of allele frequencies of point mutations (single-nucleotide variant,
and adjacent tumor tissue of MSK-PCa2 and MSK-PCa7. Most points lie on the
(E) Scatterplot of allele frequencies of expressed SNVs determined by RNA-seq
expressed subset of SNV’s, the allele frequencies lie on the regression line sugg
(F) Scatterplot of allele frequencies of SNVs determined by whole-exome DNA se
year prior of MSK-PCa1 and MSK-PCa5. The red dots indicate mutations found
common mutations, indicating that they have gained allele frequency from primar
tumor purity of the lymph node specimen. See also Figure S2, Tables S1, S2, anhas silenced AR but has retained epithelial differentiation genes
includingCK8, EPCAM, andCDH1 (E-cadherin). MSK-PCa4, the
neuroendocrine sample, expresses synaptophysin (SYP), chro-
mogranin A (CHGA) and NCAM (CD56) but no epithelial cytoker-
atins. MSK-PCa6 shows expression of squamous basal keratins
as well as the squamous/basal transcription factor TP63, consis-
tent with its histology.
In the three tumor samples with sufficient fresh frozen tumor
for which documented matching mutation profiles exist (MSK-
PCa2, MSK-PCa6, and MSK-PCa7), we further performed
RNA-seq on the in situ tumor specimens. There is a high concor-
dance of gene expression between the tumor and the organoid
lines, suggesting that in vitro culture maintains the differentiation
state of the tumor (Figure 4A). The prostate cancer organoid lines
encompass a surprising phenotypic diversity of aberrant differ-
entiation states from patients that all had adenocarcinoma in
their initial biopsy of the primary disease. This highlights the
plasticity of CRPC under selection pressure of treatment, and
is appreciated by expression analysis of primary prostate cancer
and CRPC samples from the Michigan data set (Grasso et al.,
2012) (Figures S4C–S4H).
Loss of PTEN, TP53, and RB Tumor Suppressor
Pathways in Patient-Derived Organoid Lines
The availability of comprehensive data on copy number alter-
ation, mutation, and expression provided an opportunity to
examine the frequency of pathway alteration across the panel
of organoid lines that may help identify alterations involved in
progression to CRPC. Biallelic PTEN loss was seen in all six
CRPC-derived lines but not in the hormone-sensitive MSK-
PCa7 (Figures 5A and 5B).PTEN loss has been functionally asso-
ciated with castration resistance (Carver et al., 2011) and loss of
PTEN function through copy number loss (blue), mutation
(green), or decreased expression is common in CRPC (30/36
samples) but only in 10% of primary cancer (Figure 5C and
data not shown) (Baca et al., 2013; Barbieri et al., 2012; Taylor
et al., 2010). Likewise, TP53which is mutated in 4/6 CRPC orga-
noid lines, is mutated, exhibits copy number loss or is underex-
pressed in 27/36 CRPC samples but rarely in primary cancers
(Figure 5D).
Prior studies have documented heterozygous loss RB1 in
prostate cancer, suggesting haploinsufficiency is sufficient to
promote tumorigenesis (Sharma et al., 2010). Of note, three
organoid lines had heterozygous RB1 loss (MSK-PCa1, MSK-
PCa4, and MSK-PCa5) but had no detectable RB1 transcript
or RB protein expression (Figures 5A and 5B). RNA-seq analysis
revealed complete RB1 deletion in MSK-PCa5 that was missedputative functional oncogenic significance. The genes are color-coded byRNA-
reads (RPKM). See also Figure S2 for view of TP53 and SPOPmutations. See
mutation-associated gene expression.
SNV) determined by whole-exome DNA sequencing between organoid sample
regression line, suggestion preservation of the mutational landscape.
sequencing between organoid sample and adjacent tumor tissue. Among the
esting preservation of the mutational landscape.
quencing between organoid sample and FFPE lymph node metastasis from 1
only in the organoid line. Some mutations lie above the regression line of the
y tumor to organoid line. The slope of the regression line of0.6 suggests 60%
d S3.
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Figure 3. Histology of In Situ Prostate Cancer, 3D Organoids, and
Xengrafts
(A) H&E of prostatectomy specimen of patient MSK-PCa1.
(B) H&E of organoids of MSK-PCa1.
(C) H&E of subcutaneous xenograft of MSK-PCa1.
(D) H&E of right acetabulum with metastatic prostate cancer from patient
MSK-PCa2.
(E) H&E of organoids of MSK-PCa2.
(F) H&E of renal capsule xenograft of MSK-PCa2.
182 Cell 159, 176–187, September 25, 2014 ª2014 Elsevier Inc.on array-CGH and WES (Figure S1C), possibly explained by
copy-neutral genomic rearrangement of the remaining allele.
To explore whether complete loss of RB1may be more common
in prostate cancer than previously appreciated, we examined the
RB1 gene locus and mRNA levels in a clinical CRPC data set
(Grasso et al., 2012) and found homozygous loss and reduced
expression in 70% of cases (Figure 5E). Interestingly, two
lines without RB1 alterations (MSK-PCa3 and MSK-PCa6)
have biallelic loss of the tumor suppressor locus CDKN2A (Fig-
ures S5A and S5B), providing another mechanism to disable
RB pathway function. Consistent with CDKN2A gene loss,
these two lines have hyperphosphorylated RB as a consequence
of unrestrained CDK4/6 kinase activity due to loss of p16.
CDKN2A deletion is seen rarely in clinical CRPC samples
among the RB intact subset (3/67 total samples, 4.5%). Rather,
most CRPC tumors exhibit CDKN2A overexpression, likely due
p53/RB loss (Figure 5F). Indeed, the organoid lines with RB
protein loss and P53 mutation had increased p16 expression
(Figure 5B).
Patient-Derived Organoid Lines as Genetically
Manipulatable Models for Drug Response
To explore the suitability of CRPC-derived organoid lines for
drug testing, we performed growth assays to determine sensi-
tivity to enzalutamide aswell as to two PI3-kinase pathway inhib-
itors, everolimus and BKM-120, that are currently in clinical trials
for CRPC (Figures 6A–6C). The AR-amplified MSK-PCa2 line
was exquisitely sensitive to enzalutamide with an IC-50 of
approximately 50 nM, whereas the other lines were resistant.
The MSK-PCa2 organoid line, which harbors both PTEN loss
and PIK3R1 mutation, was sensitive to both everolimus and
BKM-120. These organoid models are also amenable to in vivo
studies using bioluminescence to track tumor response. As
expected, AR-amplified MSK-PCa2-derived xenografts were
highly sensitive to enzalutamide, recapitulating the in vitro result
(Figures 6D and 6E), whereas AR negative MSK-PCa1 xeno-
grafts were resistant. For bothMSK-PCa1 andMSK-PCa2, ever-
olimus significantly slowed tumor growth rate but did not induce
shrinkage. Furthermore, everolimus significantly increased the
tumor response to enzalutamide in MSK-PCa2.(G) H&E of retroperitoneal metastasis from patient MSK-PCa3.
(H) H&E of organoids of MSK-PCa3.
(I) H&E of subcutaneous xenograft of MSK-PCa3.
(J) Cytology of pleural effusion from patient MSK-PCa4. Arrows point to
clusters of malignant cells.
(K) H&E of organoids of MSK-PCa4.
(L) H&E of subcutaneous xenograft of MSK-PCa4. Arrows point to mitotic
figures.
(M) H&E of prostatectomy specimen of patient MSK-PCa5.
(N) H&E of circulating tumor cell-derived organoids of MSK-PCa5.
(O) H&E of subcutaneous xenograft of MSK-PCa5.
(P) H&E of extraprostatic prostate cancer from cystoprostatectomy specimen
of patient MSK-PCa6. The field shown contains both adenocarcinoma and
squamous differentiation highlighted in the dotted area.
(Q) H&E of organoids of MSK-PCa6.
(R) H&E of subcutaneous xenograft of MSK-PCa6.
(S) H&E of organoids of MSK-PCa7.
(T) H&E of organoids derived of MSK-PCa7.
Scale bars represent 50 mM. See also Figure S3 for accompanying IHC.
A B Figure 4. Prostate Cancer Organoids
Exhibit Diverse Gene Expression Profiles
(A) Heatmap of RNA expression of selected genes
of seven organoid samples and three matched
tumor samples (MSK-PCa2T, MSK-PCa6T, MSK-
PCa7T) annotated in blue font. The genes are
grouped by prostate cancer subclasses (ERG,
SPINK1), prostate lineage transcription factors
(FOXA1, HOXB13, AR), androgen receptor target
genes (FKBP5, KLK2, KLK3, NKX3-1, TMPRSS2,
STEAP1), a prostate lineage AR suppressed gene
PSMA (FOLH1), epithelial markers (CK8, EPCAM,
E-cadherin:CDH1), neuroendocrine markers (syn-
aptophysin A:SYP, NCAM:CD56, chromogranin
A:CHGA), genes whose expression is associated
with epithelial to mesenchymal transition (FOXA2,
N-cadherin:CDH2, vimentin: VIM, N-myc:MYCN,
aurora kinase A: AURKA), and squamous markers
(TP63, KRT5, KRT6A). For each gene, the ex-
pression was log2 transformed and heatmap range
is from minimum to maximum.
(B) Western blot of selected proteins validating
mRNA expression. Note pancytokeratin recog-
nizes a pattern of low and high-molecular weight
keratins. MSK-PCa6 displays a range similar to normal prostate organoids that contain both basal and luminal cells, and MSK-PCa4 has lost expression of all
cytokeratins. See also Figure S4 for hierarchical clustering of organoid mRNA expression and gene expression analysis of Michigan CRPC data set.
See also Figures S1 and S4.DISCUSSION
The past few years have seen a dramatic increase in the num-
ber of approved therapies, with several promising investiga-
tional agents in late stage development to treat CRPC. These
include the next-generation antiandrogen enzalutamide and
the androgen synthesis inhibitor abiraterone acetate, both of
which have been shown to significantly prolong life (de Bono
et al., 2011; Ryan et al., 2012; Scher et al., 2012). The response,
however, is highly variable and only 30% attain durable
response of >6 months (Rathkopf and Scher, 2013). Thus, both
an improved understanding of the molecular determinants of
resistance to these agents as well as development of novel ther-
apeutics are needed. Progress has been hampered by the lack of
in vitro models that accurately represent the spectrum of
disease. Here, we describe a method that allows for the estab-
lishment of patient-derived 3D organoid lines. As this report rep-
resents our initial attempt, we anticipate the method can be
further optimized to improve the success rate to generate the
large repository of organoid lines required to study this highly
heterogeneous disease. Biopsy and characterization of meta-
static lesions are increasingly incorporated into therapeutic
clinical trials of targeted agents in prostate cancer. This clinical
practice should increase the opportunity to generate more orga-
noid lines and may allow characterization of tumor genomes
from biopsy material with too few tumor cells for direct analysis
(e.g., MSK-PCa1, MSK-PCa2, and CTC sample MSK-PCa5).
Under selection pressure from treatment, CRPC is a highly
heterogeneous disease. The widespread use of increasingly
more efficacious AR pathway inhibitors may further generate
multiple discrepant resistance mechanisms. CRPC tumor cells
may remain dependent on AR or AR-like activity, or they may
dedifferentiate into AR-independent cells (Arora et al., 2013; Bal-bas et al., 2013; Beltran et al., 2011; Carver et al., 2011; Chen
et al., 2013). The CRPC organoid lines described here already
display a broad spectrum of AR levels as well as AR transcrip-
tional activity. The generation of more lines with defined treat-
ment histories should accelerate our mechanistic understanding
of molecular determinants of sensitivity.
Prostate cancers harbor several disease-specific mutations,
including ETS-translocations, SPOP mutations, FOXA1 muta-
tions, and CHD1 loss. We have generated models of each of
these prostate-specific alterations and anticipate that more will
be generated in the near future. Additionally, CRPC organoids
provide an opportunity to define genetic lesions that mediate
progression to metastatic CRPC. The high frequency of RB
and TP53 pathway dysfunction in the CRPC organoid lines sug-
gests that drugs targeting these pathways should become a
therapeutic priority.EXPERIMENTAL PROCEDURES
Isolation and Culture of Metastatic Prostate Cancer Cells
and Circulating Tumor Cells
BetweenDecember 2012 toNovember 2013, we collected 32metastasis sam-
ples with documented tumor content >10% of the cells on pathology review
(18 bone, 9 lymph node, 2 liver, 1 brain, 1 bladder, and 1 pleural effusion)
and 17 blood from patients with high CTC count > 100 cells per 10 ml of blood.
Please see Extended Experimental Procedures for clinical details of the seven
organoid lines.
All patients provided informed consent and samples were procured and the
study was conducted under Memorial Sloan-Kettering Cancer Center Institu-
tional Review Board approval (MSKCC IRB 90-040 or 06-107) prior to tissue
acquisition. Clinical and pathologic data were entered and maintained in a
database by our research project coordinator who generated a separate ano-
nymized database for investigators. Metastatic prostate cancer biopsy pieces
were minced and digested in 5 ml of 5 mg/ml collagenase type II (Invitrogen) in
Advanced DMEM/F12 (ADMEM/F12) and digested for 0.5–2 hr at 37C withCell 159, 176–187, September 25, 2014 ª2014 Elsevier Inc. 183
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Figure 5. Loss of Tumor Suppressors
PTEN, TP53, RB1, and CDKN2A in Prostate
Organoid Lines
(A) Oncoprint view of PTEN, TP53, RB1, and
CDKN2A. The fill of the rectangle denotes
copy number change (homozygous deletion dark
blue, heterozygous deletion light blue, GAIN: red).
The border of the rectangle denotes gene expres-
sion change. Green square denotes mutation.
(B) Western blot of PTEN, RB, phosphorylated RB
(S807/S811), p16, and GAPDH of normal prostate
organoids and prostate cancer organoid lines.
(C–E) Gene expression of PTEN, TP53, and RB1 in
normal prostate tissue, primary cancer, and CRPC
from the Michigan data set. For CRPC, copy
number and mutational data are available for most
samples. Open circles indicates that mutational/
copy number data are not available. Green fill in-
dicates mutation. Light and dark blue fill indicates
heterozygous and homozygous loss.
(F) Scatter plot of gene expression of RB1 and
CDKN2A in benign (orange triangle), primary
cancer (pink square), and CRPC (black circles).
See also Figure S5 for RNA-seq and Array-CGH
tracks of CDKN2A.gently shaking. Dissociated cells were washed and seeded in growth factor
reduced Matrigel (BD biosciences).
For isolation of CTC, 8 ml of blood samples was drawn into a heparin
tube at Memorial Sloan-Kettering Cancer Center. Blood was incubated
with 400 ml RosetteSep Human CD45 Depletion Cocktail (Stem Cell Technol-
ogies) for 20 min at room temperature, then depleted of the red blood cell
and white blood cell using Ficoll-Paque (GE). Isolated circulating tumor
cells were washed and seeded in growth factor reduced Matrigel (BD
biosciences).
Human prostate cancer organoidswere passaged either via trituration with a
glass Pasteur pipet or dissociation with TrypLE (Sigma-Aldrich) for 5 min at
37C. Passage was performed weekly with a 1:3 ratio.
RNA-Sequencing and Analysis
RNA was isolated from organoids with low passage number (less than 5) using
QIAGEN RNeasy kits. Library preparation and RNA sequencing was per-
formed by MSKCC Genomics Core Laboratory using Illumina HiSeq with 50
or 75 bp paired-end reads, and 30 million reads were generated for each
sample. The reads were mapped human genome reference sequence
(GRC37/hg19) using STAR (ver 2.3) (Dobin et al., 2013) and quantified into
RPKM using Cufflinks with upper quartile normalization (ver 2.1) (Roberts
et al., 2011). Heatmaps and clustering analysis using PearsonCorrelation were
generated using GENE-E (http://www.broadinstitute.org/cancer/software/
GENE-E). Representative regions are displayed using Integrated Genomics
Viewer (IGV, http://www.broadinstitute.org/igv/).
DNA Extraction, Quality Control Library Preparation
DNA from the seven tumor organoid samples was extracted using Nucleospin
tissue XS (Clontech) according to manufacturers protocol for cultured cells.
The buffy coat DNA of the cases except MSK-PCa2 was extracted using
Nucleospin tissue XS (Clontech) according to manufacturers protocol for
blood samples. PromegaMaxwell 16 systemwas used to extracted DNA fresh
frozen tissue. MSK-PCa2 normal DNA was extracted from 5 FFPE tissue curls
using Promega Maxwell FFPE Plus LEV system.
Copy Number Analysis
Array-CGH using the Agilent SurePrint G3 1M microarray was performed
using manufacturer’s instructions by the MSKCC genomics core facility.
We used either Promega pool’s male DNA or patient normal DNA as the
hybridization control. Segmentation and discrete copy number calls was
performed using with Circular Binary Segmentation (Taylor et al., 2010).184 Cell 159, 176–187, September 25, 2014 ª2014 Elsevier Inc.We uploaded prior Agilent 244A Array CGH data of existing prostate cancer
cell lines from NCBI Gene Expression Omnibus (GSE21032) for analysis
(22RV1, DU145, LAPC4, LNCaP, PC3, and VCAP) (Taylor et al., 2010).
Data was mapped to human genome reference sequence (GRC37/hg19).
Representative regions are displayed using Integrated Genomics Viewer
(IGV).
Whole-Exome Sequencing and Data Analysis
The DNA library of the samples was prepared according to the Agilent
SureSelectXT2 Target Enrichment System, which covers about 51 Mb
of genomic regions corresponding to protein coding genes using 1 mg
input DNA.
Paired-end sequencing (23 75 bp) was then performed using Illumina HiSeq
2500. Samples were multiplexed (2 samples per lane) to ensure a nominal
coverage of 2503 per sample. Raw sequences were aligned to the human
genome reference sequence (GRC37/hg19) using BWA (Li and Durbin,
2010). We attained a mean of average coverage of 1423 across samples
with all samples showing more than 1003 average coverage in the captured
regions (range 103–178). On average, about 91% of captured bases were
covered at >103 (Table S1). We then applied GATK base quality score recali-
bration, indel realignment, duplicate removal to remove potential artifacts and
increase the quality of the alignment (McKenna et al., 2010).
Single-nucleotide variant calls were performed using an in-house computa-
tional tool via the comparison of the tumor or organoid—with its corresponding
normal control. Indel analysis was performed using GATK according to best
practices. Somatic events only, i.e., present in the tumor but not in the match-
ing controls, are then refined by depth of coverage, variant allele frequency in
the tumor, and control to filter out low quality calls. The final list is converted
into a MAF file format.
Query of mutations in other prostate cancer data sets was done through the
MSKCC computational biology portal (www.cbioprotal.org) (Cerami et al.,
2012).
Cell Viability and Proliferation Assay
Cell viability assays were conducted by plating 5,000 organoids cells per well
of a collagen coated 96-well cell culture plate in 100 ml complete humanmedia
with 0.1 nM DHT and treated with vehicle (DMSO) control or enzalutamide
(0.01–500 nM), everolimus (0.25–50 nM), BKM120 (0.05–5 mM). Viable cells
were counted using a CellTiter-Glo (Promega) Luminescent Cell Viability
Assay. All cell viability experiments were conducted in quadruplicate and stan-
dard deviations were reported.
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Figure 6. Sensitivity to AR and PI3K Inhibitor
in Organoid Lines In Vitro and In Vivo
(A–C) Dose-response curves of organoid lines to
enzalutamide, everolimus, and BKM120. Growth
was measured in quadruplet and viability was as-
sayed 4 days after treatment at the indicated drug
concentrations (mean ± SD).
(D–E) Growth of MSK-PCA1 and MSK-PCA2 xe-
nografts. Treatment was started with tumors reach
an average size of 400 mm3. Each tumor was
normalized to the pretreatment size. (n = 10,
mean ± SEM). p value derived from unpaired two-
tailed t test of normalized tumor size at the end of
treatment. Ev: everolimus, Enz: enzalutamide,
Cast: castration.Xenograft Studies
All mouse experiments was performed under MSKCC IACUC approved proto-
col. For subcutaneous growth, 2–4million cells weremixed 50:50 withMatrigel
and injected into mice CB17 SCID mice. For renal capsule growth, 100K cells
were mixed into collagen plug and implanted under the renal capsule of CB17
SCID mice.
Drug treatment was started when tumors reached 500 mm3. Everolimus
(Novartis) was dissolved in water and dosed at 10 mg/kg dose 5 days per
week. Enzalutamide was dissolved in vehicle (1% carboxymethyl cellulose,
0.1% Tween-80, 5% DMSO) and used at 10 mg/kg dosed 5 days per
week. Tumors size was measured twice weekly or weekly depending on
growth rate.
Repositories
The organoid lines will be distributed by MSKCC in compliance to the IRB-
approved informed consent signed by the patient. Genetics data from
array-CGH, RNA-seq, and whole-exome sequencing can be analyzed and
downloaded from the MSKCC cBioportal (http://www.cbioportal.org) (Cerami
et al., 2012).
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